透析療法ネクスト　IX

出版社： 医学図書出版
著者：
発行日： 2009-06-01
分野： 臨床医学：内科  >  腎臓
ISBN： 9784871513593
電子書籍版： 2009-06-01
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,860 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

商品紹介

現時点でのcinacalcetの情報と臨床経験を網羅。

目次

  • 透析療法ネクスト　IX

    ―目次―

    座談会
    　シナカルセトをより有効に使用するために

    特集　CKD-MBD管理の新時代：Cinacalcetへの期待と展望
    　わが国のCKD-MBDの疫学と管理状況―JSDTガイドらにから―
    　Cinacalcetとミネラル管理：JSDTガイドラインの達成は可能か
    　二次性副甲状腺機能亢進症とcinacalcet
    　シナカルセトと腎性骨異栄養症
    　Cinacalcetと血管石灰化
    　CinacalcetによるCKD-MBD治療アルゴリズムと適切な投与方法
    　腹膜透析患者の二次性副甲状腺機能亢進症の病態と
    　　シナカルセトの効果
    　Cinacalcetの副作用とその対策
    　シナカルセト塩酸塩の臓器選択性に関する考察
    　CKD-MBD治療におけるCinacalcetの役割：将来への展望
    　透析治療の歴史(9)―透析膜の歴史―

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

特集 『CKD - MBD管理の新時代 : Cinacalcetへの期待と展望』

P.28 掲載の参考文献
1) Moe S, Drueke T, Cunningham J, et al. : Kidney Dlsease : Improving Global Outcomes (KDIGO). : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006.
PubMed
2) Massry S : K/DOQI Clinical Practice Guidelines Am J Kidney Dis 42 : Suppl 3, S1-201, 2003.
 
3) 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006.
 
4) Fournier AE, Bordier PJ, Gueris J, et al. : 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease. Proc. Eur. Dial. Transplant. Assoc 12 : 227-236, 1976.
PubMed
5) Pierides AM, Ward MK, Alvarez-Ude F, et al. : Long term therapy with 1, 25 (OH) 2D3 in dialysis bone disease. Proc. Eur. Dial. Transplant. Assoc l2 : 237-244, 1976.
 
6) Hercz G, Kraut JA, Andress DA, et al. : Use of calcium carbonate as a phosphate binder in dialysis patients. Miner. Electrolyte Metab 12 (5-6) : 314-319, 1986.
PubMed
7) Slatopolsky E, Weerts C, Thielan J, et al. : Marked Suppression of Secondary Hyperparathyroidism by Intravenous Administration of 1, 25-Dihydroxycholecalciferol in Uremic Patients. J Clin Invest 74 : 2136-2143, 1984.
PubMed
8) Tsukamoto Y, Nomura M, Marumo F : Pharmacological parathyroidectomy by oral 1, 25 (OH) 2D3 pulse therapy. Nephron 51 : 130-131, 1989.
PubMed
9) Cohen-Solal ME, Cebert JL, Boudaillez B, Fournier A, et al. : Non-aluminic adynamic bone disease in non-dialysed uraemic patients : A new type of osteopathy due to over-treatment? Bone 13 ; 1-5, 1992.
 
10) Hercz G, Pei Y, Greenwood C, Sherrand DJ, et al. : Aplastic osteodystrophy without aluminum : the role of "suppressed" parathy-roid function. Kidney Int 44 (4) : 860-866, 1993.
 
11) Slinin Y, Foley RN, Collins AJ : Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients : the USRDS waves l, 3, and 4 study. J Am Soc Nephrol 16 : 1788-1793, 2005.
 
12) Block GA, Hulbert-Shearon TE, Levin NW, et al. : Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients : a national study. Am J Kidney Dis 13 : 607-617, 1998.
 
13) Block GA, Klassen PS, Lazarus JM, et al. : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004.
PubMed
14) Yokoyama K, Ohkido I, Nakao M, et al. : The calcium-phosphorus in guidelines for CKDMBD. Kidney Int 2008, in press
 
15) Slatopolsky E, Finch J, Brown A : New vitamin D analogs. Kidney Int (Suppl 85) : S83-87, 2003.
PubMed
16) Guerin AP, London GM, Marchais SJ, et al. : Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15 : 1014-1021, 2000.
PubMed
17) Goodman WG, Goldin J, Kuizon BD, et al. : Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 : 1478-1483, 2000.
PubMed
18) Chertow GM, Burke SK, Raggi P ; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002.
 
19) Block GA, Spiegel DM, Ehrlich J, et al. : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005.
PubMed
20) Chertow GM, Raggi P, Chasan-Taber S, et al. : Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19 (6) : 1489-1496, 2004.
 
21) Galassi A, Spiegel DM, Bellasi A, et al. : Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 21 (11) : 3215-3222, 2006.
PubMed
22) Qunibi W, Moustafa M, Muenz LR, et al. : CARE-2 Investigators A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control : the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51 (6) : 952-965, 2008.
 
23) Caglar K, Yilmaz MI, Saglam M, et al. : Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 3 (1) : 61-68, 2008.
PubMed
24) Block GA, Raggi P, Bellasi A, et al. : Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71 (5) : 438-441, 2007.
PubMed
25) Suki WN, Zabaneh R, Cangiano JL, et al. : Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int Nov 72 (9) : 1130-1137, 2007.
PubMed
26) わが国の慢性透析療法の現況2005年12月31日現在. 日本透析医学会
 
27) Arenas MD, Alvarez-Ude F, Gil MT, et al. : Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease : changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 21 : 1663-1668, 2006.
PubMed
28) わが国の慢性透析療法の現況2006年12月31日現在. 日本透析医学会
 
29) Jean G, Chazot C, Charra B : 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism : Effect on bone markers. Clin Nephrol 68 (1) : 63-64, 2007.
 
30) Sterrett JR, Strom J, Stummvoll HK, et al. : Cinacalcet HCl (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68 (1) : 10-17, 2007.
 
31) Moe SM, Chertow GM, Coburn JW, et al. : Achieving NKF-K/DOQI bone metabollsm and disease treatment goals with cinacalcet HCl. Kidney Int 67 (2) : 760-771, 2005.
 
32) Messa P, Macario F, Yaqoob M, et al. : The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 (1) : 36-45, 2008
PubMed
33) Fukagawa M, Yumita S, Akizawa T, et al. : KRN1493 study group. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 (1) : 328-335, 2008.
 
34) Cunningham J, Danese M, Olson K, et al. : Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 (4), 1793-1800, 2005.
PubMed
35) St Peter WL, Li Q, Liu J, et al. : Cinacalcet Use Patterns and Effect on Laboratory Values and Other Medications in a Large Dialysis Organization, 2004 through 2006. Clin J Am Soc Nephrol, 2009 Jan 7. [Epub ahead of print]
 
36) Chertow GM, Blumenthal S, Turner S, et al. : CONTROL Investigators. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) : rationale and design overview. Clin J Am Nephrol 2 (5) : 898-905, 2007.
 
37) http://www.kdigo.org/
 
38) わが国の慢性透析療法の現況2007年12月31日現在. 日本透析医学会
 
P.43 掲載の参考文献
1) Eknoyan G, Levin A, Levin N : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3) : S1-S201, 2003.
 
2) 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006.
 
3) Young EW, Akiba T, Albert JM, et al. : Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 : 34-38, 2004.
PubMed
4) Goodman WG, Hladik GA, Turner SA, et al. : The calcimimetic agent AMG 073 lowers plasm parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13 : 1017-1024, 2002.
 
5) Quarles LD, Sherrard DJ, Adler S, et al. : The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14 : 575-583, 2003.
PubMed
6) Block GA, Martin KJ, de Francisco ALM, et al. : Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 : 1516-1525, 2004.
PubMed
7) Lindberg JS, Culleton B, Wong G, et al. : Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis : a randomized, double-blind, multicenter study. J Am Soc Nephrol 16 : 800-807, 2005.
PubMed
8) Moe SM, Chertow GM, Coburn JW, et al. : Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 : 760-771, 2005.
PubMed
9) Sterrett JR, Strom J, Stummvoll HK, et al. : Cinacalcet HCl (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68 : 10-17, 2007,
 
10) Fishbane S, Shapiro WB, Corry DB, et al. : Cinacalcet HCL and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone : the ACHIEVE study results. Clin J Am Soc Nephrol 3 : 1718-1725, 2008.
PubMed
11) Messa P, Macario F, Yaqoob M, et al. : The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 : 36-45, 2008.
PubMed
12) Komaba H, Fukagawa M : lmpact of cinacalcet hydrochloride on the achievement of the Japan Society for Dialysis Therapy (JSDT) guideline targets : a post-hoc analysis of the KRN 1493 study. Ther Apher Dial 12 (Suppl 1) : S44-S49, 2008.
 
13) Frazao J, Rodriguez M : Secondary hyperparathyroidism disease stabilization following calcimimetic therapy. Nephrol Dial Transplant Plus 1 (Suppl 1) : i12-i17, 2008.
 
14) Ceglia L, Harris SS, Rasmussen HM, et al. : Activation of the calcium sensing receptor stirnulates gastrin and gastric acid secretion in healthy participants. Osteoporos Int 20 : 71-78, 2009.
PubMed
15) Diez JJ, Miguel JL, Codoceo R, et al. : Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis. Nephrol Dial Transplant 23 : 1387-1395, 2007.
PubMed
16) Fukagawa M, Yumita S, Akizawa T, et al. : Cinacalcet (KRNI493) effectively decreases the serum intact PTH level with favourable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008.
PubMed
17) Akiba T, Akizawa T, Tsukamoto Y, et al. : Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 12 : 117-125, 2008.
PubMed
18) Goodman WG, Hladik GA, Tuner SA, et al. : The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13 : 1017-1024, 2002.
 
19) Schaefer RM, Bover J, Dellanna F, et al. : Efficacy of cinacalcet administered with the first meal after dialysis : the SENSOR study. Clin Nephrol 70 : 126-134, 2008.
PubMed
20) Chertow GM, Blumenthal S, Turner S, et al. : Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium×phosphate. Clin J Am Soc Nephrol 1 : 305-312, 2006.
 
21) Arenas MD, Alvarez-Ude F, Gil MT, et al. : Implementation of 'K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 22 : 1639-1644, 2007.
 
22) Lazar E, Hebert K, Poma T, et al. : Longterm outcome of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism. Am J Nephrol 27 : 274-278, 2007.
PubMed
23) Block GA, Zeig S, Sugihara J, et al. : Combination therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23 : 2311-2318, 2008.
PubMed
P.54 掲載の参考文献
1) Guideline Working Group, Japanese Society for Dialysis Therapy : Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12 : 514-525, 2008.
 
2) Andress DL : Vitamin D in chronic kidney disease : a systemic role of selective vitamin Dreceptor activation. Kidney Int 69, 33-43, 2006.
 
3) Tokumoto M, Tsuruya K, Fukuda K, et al. : Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 62 : 1196-1207, 2002.
PubMed
4) Canaff L, Hendy GN : Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1, 25-dihydroxyvitamin D. J Biol Chem 277 : 30337-30350, 2002.
PubMed
5) Murayama A, Takeyama K, Kitanaka S, et al. : Positive and negative regulations of the renal 25-hydroxyvitamin D3 1 alpha-hydroxy-lase gene by parathyroid hormone, calcitonin, and lalpha, 25 (OH) 2D3 in intact animals. Endocrinology 140 : 2224-2231, 1999.
 
6) Taniguchi M, Tokumoto M, Matsuo D, et al. : Parathyroid growth and regression in experimental uremia. Kidney Int 69 : 464-470, 2006.
PubMed
7) Fukagawa M, Okazaki R, Takano K, et al. : Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 323 : 421-422, 1990.
PubMed
8) Quarles LD, Yohay DA, Carroll BA, et al. : Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45 : 1710-1721, 1994.
PubMed
9) Taniguchi M, Tokumoto M, Matsuo D, et al. : Persistent hyperparathyroidism in renal allograft recipients : vitamin D receptor, calcium-sensing receptor and apoptosis. Kidney Int 70 : 363-370, 2006.
PubMed
10) Denda M, Finch J, Slatopolsky E : Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28 : 596-602, 1996.
PubMed
11) Taniguchi M, Tokumoto M, Tsuruya K, et al. : Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. Nephrol Dial Transplant 23 : 3662-3669, 2008.
 
12) Fukagawa M, Yumita S, Akizawa T, et al. : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in J apanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2007.
 
13) Serra AL, Schwarz AA, Wick FH, et al. : Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persist hyperparathyroidism. Nephrol Dial Transplant 20 : 1315-1319, 2005.
PubMed
14) Kruse AE, Eisenberger U, Frey FJ, et al. : The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 20 : 1311-1314, 2005.
PubMed
15) Fukagawa M, Taniguchi M : Can calcimimetics inhibit nodular hyperplasia of parathyroid glands? Nephrol Dial Transplant 23 : 407-408, 2008.
PubMed
16) Chertow GM, Pupim LB, Block GA, et al. : Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) : rationale and design overview. Clin J Am Soc Nephrol 2 : 898-905, 2007.
PubMed
17) Rodriguez ME, Almaden Y, Canadillas, et al. : The calcimimetics R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 292 : F1390-1395, 2007.
PubMed
18) Colloton M, Shatzen E, Miller G, et al. : Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroism. Kidney Int 67 : 467-476, 2005.
 
19) Block GA, Zeig S, Sugihara J, et al. : Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23 : 2311-2318, 2008.
PubMed
20) Teng M, Wolf M, Ofsthun MN, et al. : Activated injectable vitamin D and hemodialysis survival : a historical cohort study. J Am Soc Nephrol 16 : 1115-1125, 2005.
PubMed
21) Jono S, Nishizawa Y, Shioi A, et al. : 1, 25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98 : 1302-1306, 1998.
PubMed
P.63 掲載の参考文献
1) Levin A, Bakris GL, Molitch M, et al. : Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease : results of the study to evaluate early kidney disease. Kidney Int 71 : 31-38, 2007.
 
2) Chonchol M, Scragg R : 25-hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 71 : 134-139, 2007.
PubMed
3) National Kidney Foundation : K/DOQI clinical guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3) : S1-S202, 2003.
 
4) Zisman AL, Hristova M, Ho LT, et al. : Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27 : 36-43, 2007.
PubMed
5) Al-Aly Z, Qazi RA, Gonzalez EA, et al. : Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 50 : 59-68, 2007.
PubMed
6) Dusso AS, Brown AJ, Slatopolsky E : Vitamin D. Am J physiol Renal Physiol 289 : F8-F28, 2005.
PubMed
7) Maalouf NM : The noncalciotropic actions of vitamin D : recent clinical developments. Curr Opin Nephrol Hypertens 17 : 408-415, 2008.
PubMed
8) Abe E, Miyaura C, Sakagami H, et al. : Differentiation of mouse myeloid leukemia cells induced by 1α, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78 : 4990-4994, 1981.
 
9) Zittermann A : Vitamin D in preventive medicine : are we ignoring the evidence? Br J Nutr 89 : 552-572, 2003.
PubMed
10) Liu M, Lee MH, Cohen M, et al. : Transcriptional activation of the Cdk inhibitor p21 by vitamin D31eads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10 : 142-153, 1996.
 
11) Li P, Li C, Zhao X, et al. : p27 (Kip1) stabilization and Gl arrest by 1, 25-dihydroxyvitamin D3 in ovarian cancer cells mediated through down-regulation of cyclin E/cyclindependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem 279 : 25260-25267, 2004.
 
12) Cordero JB, Cozzolino M, Lu Y, et al. : 1, 25-Dihydroxyvitamin D downregulates cell membrane growth-and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem 277 : 38965-38971, 2002.
PubMed
13) Ji Y, Studzinski GP : Retinoblastoma protein and CCAAT/enhancer-binding protein beta are required for 1, 25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells. Cancer Res 64 : 370-377, 2004.
PubMed
14) Liu PT, Stenger S, Li H, et al. : Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 : 1770-1773, 2006.
PubMed
15) Mathieu C, Waer M, Laureys J, et al. : Prevention of autoimmune diabetes in NOD mice by 1, 25 dihydroxyvitamin D3. Diabetologia 37 : 552-558, 1994.
PubMed
16) Mathieu C, Adorini L : The coming of age of 1, 25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med 8 : 174-179, 2002.
PubMed
17) Cantorna MT, Hayes CE, DeLuca HF : 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 93 : 7861-7864, 1996.
 
18) Porsti IH : Expanding targets of vitamin D receptor activation : downregulation of several RAS components in the kidney. Kidney Int 74 : 1371-1373, 2008.
PubMed
19) Chertow BS, Sivitz WI, Baranetsky NG, et al. : Cellular mechanisms of insulin release : the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 113 : 1511-1518, 1983.
PubMed
20) Christakos S, Friedlander EJ, Frandsen BR, et al. : Studies on the mode of action of calciferol. XIII. Development of a radioimmunoassay for vitamin D-dependent check intestinal calcium-binding protein and tissue distribution. Endocrinology 104 : 1495-1503, 1979.
 
21) Schwartz GG, Eads D, Rao A, et al. : Pancreatic cancer cells express 25-hydroxyvitamin D-1a-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 25 : 1015-1026, 2004.
 
22) Wu J, Garami M, Cao L, et al. : 1, 25 (OH) 2D3 suppresses expression and secretion of atrialnatriuretic peptide from cardiac myocytes. Am J physiol Endocrinol Metab 268 : E1108-E1113, 1995.
 
23) Valdivielso JM, Ayus JC : Role of vitamin D receptor activators on cardiovascular risk. Kidney Int 74 (Suppl 111) : S44-S49, 2008.
 
24) Kuhlmann A, Haas CS, Gross ML, et al. : 1, 25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotallynephrectomized rat. Am J physiol Renal Physiol 286 : F526-F533, 2004.
 
25) Szeto CC, Chow KM, Kwan BCH, et al. : Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy : an uncontrolled trial. Am J Kidney Dis 51 : 724-731, 2008.
PubMed
26) Lebwohl M : Psoriasis. Lancet 361 : 1197-2004, 2003.
PubMed
27) Reichel H, Szabo A, Uhl J, et al. : Intermittent versus continuous administration of 1, 25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism. Kidney Int 44 : 1259-1265, 1993.
PubMed
28) 日本透析医学会ワーキンググループ : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006.
 
29) Kovesdy CP, Kalantar-Zadeh K : Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 73 : 1355-1363, 2008.
PubMed
30) Tominaga Y, Inaguma D, Matsuoka S, et al. : Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher and Dial 10 : 198-204, 2006.
PubMed
31) Fukagawa M, Yumita S, Akizawa T, et al. : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008.
PubMed
32) Block GA, Zeig S, Sugihara J, et al. : Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23 : 2311-2318, 2008.
PubMed
33) Canaff L, Hendy GN : Human calcium-sensing receptor gene : vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1, 25-dihydroxyvitamin D. J Biol Chern 277 : 30337-30350, 2002.
 
34) Rodriguez ME, Almaden Y, Canadillas S, et al. : The calcimimetics R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 292 : F1390-Fl395, 2007.
PubMed
P.71 掲載の参考文献
1) Tominaga Y, Tanaka Y, Sato K, et al. : Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13 : 78-86, 1997.
PubMed
2) Komaba H, Tanaka M, Fukagawa M : Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Intern Med 47 : 989-994, 2008.
PubMed
3) 田中元子, 深川雅史 : 副甲状腺インターベンションの種類と適応 : 黒川清, 深川雅史編 : 新しい透析骨症. 日本メデイカルセンター, 東京 : 210-214, 2003.
 
4) Block GA, Martin KJ, de Francisco AL, et al. : Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 : 1516-1525, 2004.
PubMed
5) Colloton M, Shatzen E, Miller G, et al. : Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67 : 467-476, 2005.
 
6) Rodriguez ME, Almaden Y, Caiadillas S, et al. : The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 292 : F1390-F1395, 2007.
 
7) Mizobuchi M, Ogata H, Hatamura I, et al. Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochem Biophys Res Commun 362 : 11-16, 2007.
PubMed
8) Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and healthrelated quality of life in secondary hyperparathyroidism. Kidney Int 68 : 1793-1800, 2005.
PubMed
9) Lindberg JS, Culleton B, Wong G, et al. : Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis : a randomized, double-blind, multicenter study. J Am Soc Nephrol 16 : 800-807, 2005.
PubMed
10) Fukagawa M, Yumita S, Akizawa T, et al. : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial transplant 23 : 328-335, 2008.
PubMed
11) Tanaka M, Nakanishi S, Komaba H, et al. : Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. NDT PIus 1 : iii49-53, 2008.
 
12) Terawaki H, Nakano H, Takeguchi F, et al. Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant 24 : 690-691, 2009.
PubMed
13) Meola M, Petrucci I, Barsotti G : Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 24 : 982-989, 2009.
PubMed
P.78 掲載の参考文献
1) Young EW, Albert JM, Satayathum S, et al. : Predictore and consequences of altered mineral metabolism : the dialysis outcomes and practice pattern study. Kidney Int 67 : 1179-1187, 2005.
 
2) Block GA, Klassen PS, Lazarus JM, et al. : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis patients. J Am Soc Nephrol 15 : 2208-2218, 2004.
PubMed
3) National kidney Foundation : K/DOQI (Kidney Disease Outcomes Quality Initiative) Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease patients : some therapeutic implications. Am J Kidney Dis 42 : S1-202, 2003.
 
4) Guideline Working Group : Japanese Society for Dialysis Therapy Clinical Practice Guideline for the Management of Secondary Hyperparathyroidism in Chronic Dialysis Patients. Therapeutic Apheresis and Dialysis 12 : 514-525, 2008.
 
5) Kakuta T, Tanaka R, Kanai G, et al. : Realationship Between the Weight of Parathyroid Glands and Their Secretion of Parathyroid Hormone in Hemodialysis Patients With Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis 12 : 385-390, 2008.
 
6) Solbiati L, Giangrande A, Pra LD, et al. : Percutaneous ethanol injection of parathyroid tumor under ultrasonic guidance : Treatment for secondary hyperparathyroidism. Radiology 155 : 607-610, 1985.
 
7) Fukagawa M, Kitaoka M, Kurokawa K : Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients : A theoretical approach. Nephrol Dial Trans 11 : 125-129, 1996.
 
8) Kakuta T, Fukagawa M, Fujisaki T, et al. : Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 33 : 1091-1099, 1999.
PubMed
9) Fukagawa M, Tominaga Y, Kitaoka M, et al. : Medical and surgical aspects of parathyroidectomy. Kidney Int 56 : S-65-S69, 1999.
 
10) Tanaka R, Kakuta T, Fujisaki T, et al. : Longterm (3 years) prognosis of parathyroid function in chronic dialysis patients after PEIT guided by colour doppler ultrasonography. Nephrol Dial Transplant 18 (supple 3) : 51-61, 2003.
 
11) Kitaoka M, Fukagawa M, Fukuda N, et al. : Direct injections of calcitriol into enlarged parathyroid glands in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1 : 563-567, 1995.
 
12) Kitaoka M, Onoda N, Kitamura H, et al. : Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism : multicentre trial. Nephrol Dial Transplant 18S : 38-41, 2003.
 
13) Shiizaki K, Hatamura H, Negi S, et al. : perctaneous Maxacalcitol injection therapy regresses hyper plasia of parathyroid and induces apoptosis in uremia. Kidney Int 64 : 992-1003, 2003.
 
14) 深川雅史, 富永芳博, 貴田岡雅史, 他 : 選択的PEITに関するガイドライン 2000 日本透析会誌 33 : 1343-1345, 2000.
 
15) 小野田教高, 深川正史, 富永芳博, 他 : 副甲状腺インターベンション研究会報告 : 選択的副甲状腺棘中量法に関するガイドライン 日本透析会誌 40 : 31-35, 2007.
 
16) 日本透析医学会ワーキンググループ : 透析患者における二次性副甲状腺機能亢進症ガイドライン. 透析会誌 39 : 1435-1455, 2006.
 
17) 冨永芳博, 貴田岡雅史, 秋澤忠男, 他 : わが国の腎性上皮小体 (副甲状腺) 機能亢進症に対する上皮小体摘出術の現況-アンケート調査結果-. 透析会誌 36 : 1361-1369, 2003.
 
18) Koiwa F, Kakuta T, Tanaka R, et al. : Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 22 : 522-528, 2007.
 
19) Fukagawa M, Yumita S, Akizawa T ; KRN1493 study group : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favourable control of the serum phosphorus and calcium levels in Japanese dialysis patients Nephrol Dial Transplant 23 : 328-335, 2008.
 
20) Mizobuchi M, Ogata H, Hatamura I, et al. : Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochemical and Biophysical Research Communications 362 : 11-16, 2007.
PubMed
21) Kawata T, Imanishi Y, Kobayashi K, et al. : Relationship between parathyroid calciumsensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. European Journal of Endocrinology 153 : 587-594, 2005.
 
22) Terawaki H, Nakano H, Takeguchi F, et al. : M. Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant 24 : 690-691, 2009.
 
P.88 掲載の参考文献
1) Nagano N : Pharmacological and clinical properties of calcimimetics : Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacology & Therapeutics 109 : 339-365, 2006.
PubMed
2) Wetmore JB, Quarles LD : Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease : time for paradigm shift? Nature Clinical Practice 5 : 24-33, 2009.
 
3) National Kidney Foundation : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 : S1-201, 2003.
PubMed
4) Moe S, Drueke T, Cunninham J, et al. : Definition, evaluation, and classification of renal osteodystrophy : A position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006.
 
5) Coburn JW, Sherrard DJ, Ott SM, et al. : Bone disease in uremia. In : Biochemical and Clinical Endocrinolgy of Calcium Metabolism (Norman AW ed) : 827-831, 1982.
 
6) Sherrad DJ, Hercz G, Pei Y, et al. : The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 43 : 436-442, 1993.
 
7) 反復経口投与時の血漿中シナカルセト濃度, および血中濃度 (2HPT患者). 総合製品概要「レグパラ錠25mg・75mg ; シナカルセト塩酸塩」協和発酵キリン株式会社 (社内資料), 2009.
 
8) Wada M, Ishii H, Furuya Y, et al. : NPS R-568 halts or reverses osteitis fibrosa in a uremic rats. Kidney Int 53 : 448-453, 1998.
PubMed
9) 骨密度・骨強度に対する作用 (部分腎摘ラット). 総合製品概要「レグパラ錠25mg・75mg ; シナカルセト塩酸塩」協和発酵キリン株式会社 (社内資料), 2009.
 
10) Miller MA, Fox J : Dialy transient decreases in plasma parathyroid hormone levels induced by the calcimimetic NPS R-568 slow the rate of bone loss but does not increase bone mass in overiectomized rats. Bone 27 : 511-519, 2000.
 
11) 栗原怜 : 骨生検からわかること, しなくてもわかること. 透析療法ネクスト II, 秋葉隆, 秋澤忠男 (編集), 医学図書出版, 東京, p49-60, 2002.
 
12) Yajima A, Inaba M, Tominaga Y, et al. : Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 74 : 775-781, 2008.
PubMed
13) Andrss DL, Norris KC, Coburn JW, et al. : Long-term low-dose calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Eng J Med 321 : 274-279, 1989.
 
14) 栗原怜, 秋葉隆, 谷澤龍彦, 他 : 維持透析患者における二次性副甲状腺機能亢進症に対するマキサカルシトール (OCT) 投与時の骨組織学的検討. 腎と透析 47 : 559-572, 1999.
 
15) Onoda N, Kurihara S, Sakurai Y, et al. : A case of secondary hyperparathyroidism whose high turnover bone improved after the direct injection of acetic acid into the parathyroid glands. Clin Nephrol 61 : 68-73, 2004.
PubMed
16) Ishii H, Wada M, Furuya Y, et al. : Daily intermittent decreases in serum levels of parathyroid hormone have anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 26, 175-182, 2000.
PubMed
17) Chen P, Miller PD, Delmas PD, et al. : Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21 : 1785-1790.
 
18) Malluche HH, Monier-Fauger MC, Wang G, et al. : An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69 : 269-277, 2008.
 
19) Yajima A, Akizawa T, Tsukamoto Y, et al. : Impact of cinacalcet hydrochloride on bone histology in patients with secondary hypereparathyroidism. Ther Apher Dia112 (suppl 1) : S38-S43, 2008.
 
20) 栗原怜 : 特集 : シナカルセト塩酸塩は二次性副甲状腺機能亢進症をどう変えたか ; 4. シナカルセト塩酸塩と骨形態-組織形態計測と骨塩量-. Nephrolgy Frontier 7 : 244-248, 2008.
 
21) Lien YH H, Silva AL, Whittman D : Effects of cinacalcet on bone mineral density in a patients with secondary hyperparathyroidism. Nephrol Dial Transplant 20 : 1232-1237, 2005.
 
22) Peacock M : Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90 : 135-141, 2005.
PubMed
23) Vestergaard P, Mosekilde L : Paratyroid surgery is associated with a deceased risk of hip and upper arm fractures in primary hyperparathyroidism : a controlled cohort study. J Intern Med 255 : 108-114, 2004.
 
24) Nomura R, Sugimoto T, Tsukamoto T, et al. : Marked and sustained increase in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism ; a six-year longitudinal study with or without parathyroidectomy in Japanese population. Clin Endcinol 60 : 335-342, 2004.
PubMed
25) Cunningham J, Danese M, Olson K, et al. : Effects of the calcimimetic cinacalcet HCl on vascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 : 1793-1800, 2005.
 
26) Lopez I, Mendoza FJ, Olson K, et al. : The effects of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 73 : 300-307, 2008
 
P.96 掲載の参考文献
1) Levy RJ, Gundberg C, Scheinman R : The identification of the vitamin K-dependent bone protein osteocalcin as one of the gamma-carboxyglutamic acid containing proteins present in calcified atherosclerotic plaque and mineralized heart valves. Atherosclerosis 46 : 49-56, 1983.
PubMed
2) Giachelli CM, Bae N, Almeida M, et al. : Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92 : 1686-1696, 1993.
PubMed
3) Dhore CR, Cleutjens Jp, Lutgens E, et al. : Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21 : 1998-2003, 2001.
PubMed
4) Jono S, McKee MD, Murry CE, et al. : Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 : E10-17, 2000.
PubMed
5) Steitz SA, Speer MY, Curinga G, et al. : Smooth muscle cell phenotypic transition associated with calcification : upregulation of Cbfal and downregulation of smooth muscle lineage markers. Circ Res 89 : 1147-1154, 2001.
 
6) Shroff RC, McNair R, Figg N, et al. : Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118 : 1748-1757, 2008.
PubMed
7) Basalyga DM, Simionescu DT, Xiong W, et al. : Elastin degradation and calcification in an abdominal aorta injury model : role of matrix metalloproteinases. Circulation 110 : 3480-3487, 2004.
 
8) Lee JS, Basalyga DM, Simionescu A, et al. : Elastin calcification in the rat subdermal model is accompanied by up-regulation of degradative and osteogenic cellular responses. Am J Pathol 168 : 490-498, 2006.
PubMed
9) Lopez I, Aguilera-Tejero E, Mendoza FJ, et al. : Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17 : 795-804, 2006.
PubMed
10) Kawata T, Nagano N, Obi M, et al. : Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 74 : 1270-1277, 2008.
PubMed
11) Koleganova N, Piecha G, Ritz E, et al. : A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 75 : 60-71, 2009.
 
12) Smajilovic S, Hansen JL, Christoffersen TE, et al. : Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 348 : 1215-1223, 2006.
PubMed
13) Alam MU, Kirton Jp, Wilkinson FL, et al. : Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 81 : 260-268, 2009.
PubMed
14) Guldbakke KK, Khachemoune A : Calciphylaxis. Int J Dermatol 46 : 231-238, 2007.
PubMed
15) Wilmer WA, Magro CM : Calciphylaxis : emerging concepts in prevention, diagnosis, and treatment. Semin Dial 15 : 172-186, 2002.
PubMed
16) Essary LR, Wick MR : Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol 113 : 280-287, 2000.
PubMed
17) Budisavljevic MN, Cheek D, Ploth DW : Calciphylaxis in chronic renal failure. J Am Soc Nephrol 7 : 978-982, 1996.
PubMed
18) Moe SM, Reslerova M, Ketteler M, et al. : Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67 : 2295-2304, 2005.
PubMed
19) Price PA, Faus SA, Williamson MK : Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 18 : 1400-1407, 1998.
PubMed
20) Bleyer AJ, Choi M, Igwemezie B, et al, : A case control study of proximal calciphylaxis. Am J Kidney Dis 32 : 376-383, 1998.
PubMed
21) Goldsmith DJ : Calcifying Panniculitis or 'simple' inflammation? Biopsy is better than a bone scan. Nephrol Dial Transplant 12 : 2463-2464, 1997.
PubMed
22) Mazhar AR, Johnson RJ, Gillen D, et al. : Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60 : 324-332, 2001.
PubMed
23) Perez-Mijares R, Guzman-Zamudio JL, Payan-Lopez J, et al. : Calciphylaxis in a haemodialysis patient : functional protein S deficiency? Nephrol Dial Transplant 11 : 1856-1859, 1996.
 
24) Rostaing L, el Feki S, Delisle MB, et al. : Calciphylaxis in a chronic hemodialysis patient with protein S deficiency. Am J Nephrol 15 : 524-527, 1995.
 
25) Robinson MR, Augustine JJ, Korman NJ : Cinacalcet for the treatment of calciphylaxis. Arch Dermatol 143 : 152-154, 2007.
PubMed
26) Mohammed IA, Sekar V, Bubtana AJ, et al. : Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant 23 : 387-389, 2008.
PubMed
27) Pallure V, Comte C, Leray-Mouragues H, et al. : Cinacalcet as first. line treatment for calciphylaxis. Acta Derm Venereol 88 : 62-63, 2008.
PubMed
28) Sharma A, Burkitt-Wright E, Rustom R : Cinacalcet as an adjunct in the successful treatment of calciphylaxis. Br J Dermatol 155 : 1295-1297, 2006.
PubMed
29) Velasco N, MacGregor MS, Innes A, et al. : Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant 21 : 1999-2004, 2006.
PubMed
P.108 掲載の参考文献
1) Akizawa T, Kinugasa E, Akiba T, et al. : Incidence and clinical characteristics of hypoparathyroidism in dialysis patients. Kidney Int 62 : S72-S74, 1997.
PubMed
2) Hamano T, Oseto S, Fujii N, et al. : Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients. Bone 36 : 909-916, 2005.
PubMed
3) Kimata N, Albert JM, Akiba T, et al. : Association of mineral metabolism factors with allcause and cardiovascular mortality in hemodialysis patients : The Japan dialysis outcomes and practice patterns study. Hemodialysis Int 11 : 340-348, 2007.
 
4) Moe SM : Treatment of chronic kidney disease-mineral bone disorder and vascular complications. Ther Apher Dial 10 : S2-S15, 2006.
 
5) Moe SM, Chertow GM, Coburn JW, et al. : Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 : 760-771, 2005.
PubMed
6) Fukagawa M, Yumita S, Akizawa T, et al. : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008.
PubMed
7) Komaba H, Fukagawa M : lmpact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets : a post-hoc analysis of the KRN1493 study. Ther Apher Dial 12 (Suppl 1) : S44-49, 2008.
 
8) Messa P, Macario F, Yaqoob M, et al. : The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 : 36-45, 2008.
PubMed
9) Fishbane S, Shapiro WB, Corry DB, et al. : Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone : the ACHIEVE study results. Clin J Am Soc Nephrol 3 : 1718-1725, 2008.
PubMed
10) Hosaka K, Kazama JJ, Yamamoto S, et al. Alterlations in serum phosphate levels predict the long-term response to intravenous calctriol therapy in dialysis patients with secondary hyperparathyroidism. J Bone Miner Metab 26 : 185-190, 2008.
 
11) Block GA, Zeig S, Sugihara J, et al. : Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23 : 2311-2318, 2008.
PubMed
12) Chertow GM, Blumenthal S, Turner S, et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 1 : 305-312, 2006.
PubMed
13) Tanaka M, Nakanishi S, Komaba H, et al. : Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. NDT Plus 1 (Suppl 3) : iii49-53, 2008.
 
14) 東純一, 古屋良宏, 内田英二 : KRN1493 (シナカルセト塩酸塩) の健康成人男子を対象とした第I相臨床試験 -反復経口投与時の薬物動態, 薬力学および安全性の検討-. Jan Pharmacol Ther (薬理と治療) 35 : 953-962, 2007.
 
15) Goodman WG, Hladik GA, Turner SA, et al. : The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13 : 1017-1024, 2002.
PubMed
16) Ohashi N, Uematsu T, Nagashima S, et al. : The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 57 : 726-734, 2004.
PubMed
17) Schaefer RM, Bover J, Dellanna F, et al. : Efficacy of cinacalcet administered with the first meal after dialysis : the SENSOR Study. Clin Nephrol 70 : 126-134, 2008.
PubMed
18) Ceglia L, Harris SS, Rasmussen HM, et al. : Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants. Osteoporos Int 20 : 71-78, 2009.
PubMed
P.120 掲載の参考文献
1) Nakai S, Wada A, Kitaoka T, et al. : An over view of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial 10 : 476-497, 2006.
 
2) TWeinreich, M Rambausek, E Ritz : Is Control of Secondary Hyperparathyroidism Optimal with the Currently Used Calcium Concentration in the CAPD Fluid? : Nephrol Dial Transplant 6 : 843-845, 1991.
 
3) Messa P, Gropuzzo M, Cleva M, et al. : Behaviour of phosphate removal with different dialysis schedules. Nephrol Dial Transplant 13 (Suppl 6) : 43-48, 1998.
 
4) 田中弘之 : 尿細管障害とミネラル骨代謝. 日本腎臓学会雑誌 49 : 422-426, 2007.
 
5), Disthabanchong S, Martin KJ, McConkey CL, et al. : Metabolic acidosis up-regulates PTH/PTHrP receptors in UMR 106-01 osteoblastlike cells. Kidney Int 62 : 1171-1177, 2002.
PubMed
6) Ignacio Lopez, Escolastico Aguillera-Tejeeo, Jose Carlos Estepa, et al. : Role of acidosis-induced increases in calcium on PTH secretion in acute metabolic and respiratory acidosis in the dog. Am J Physiol Endocrinol Metab 286 : E780-E785, 2004.
 
7) Arnett TR, Dempster DW : Effect of pH on bone resorption by rat osteoclasts in vitro. Endocrinology 119 : 119-24, 1986.
 
8) PKurz, T Tsobanelis, P Rooth, et al. : Differences in calcium kinetic pattern between CAPD and HD patients : Clinical Nephrology, 44 : 255-261, 1995.
 
9) Brown EM, Herbert SC : Acloned extracelluar Ca2+ sensing receptor from bovine parathyroid. Nature 366 : 575-580, 1993.
 
10) Lindberg JS, Culleton B, Wong G, et al. : Cinacalcet HCl, an oral calcimetric agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis : a randomized, double-blind, multicenter study. J am Soc Nephrol 16 : 800-807, 2005.
PubMed
11) 窪田実, 秋澤忠男, 塚本雄介, 他 : 腹膜透析施行中の腹膜透析患者に対するKRN1493 (シナカルセト炭酸塩) の効果-一般臨床試験 (第III相) -, 腎と透析 63 : 423-435, 2007.
 
12) William D Fraser, Aftab M Ahmad, Jiten P Vora : The Physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis : Curr Opin Nephrol Hypertens 13 : 437-444, 2004.
PubMed
13) 永野伸朗 : カルシウム受容体作動薬 (Calcimimetrics) の臨床応用と展望に関する一考察. CLINICAL CALCIUM 9 : 770-774, 1999.
 
14) Fishbane S, et al. : Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D Alone : The ACHIEVE Study Results : Clin J Am Soc Nephrol 3 (6) : 1718-1725, 2008.
PubMed
15) Minoru Kubota, Yuki Iwanaga, Nozomi Ishiguro : The Effect of Intraperitoneal 22-Oxacalcitriol on Secondary Hyperparathyroidism in Continuous Ambulatory Peritoneal Dialysis Patients (IPOX Study). Adv Perit Dial 19 : 227-230, 2003.
 
16) K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney. Am J. Kidney Disease 42 (Suppl. 3) : S12-S28, 2003.
 
17) 社団法人 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン : 日本透析医学会雑誌 39 (10) : 1435-1455, 2006.
 
18) 重松隆 : ビタミンD治療と透析液Ca濃度を考える. 透析フロンティア (0917-2114) 15巻Suppl : 4-23, 2005.
 
19) Sherrard DJ, Hercz G, Maloney NA, et al. : The spectrum of bone disease in end-stage renal failure an envolving disorder. Kidney Int 43 : 436-442, 1993.
 
20) LBRANDI, PK NIELSEN, S BRO, et al. : Long-term effects of intermittent oral alpha-calcidol, calcium carbonate and low-calcium dialysis (1. 25mmolL) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis : Journal of Internal Medicine 244 : 121-131, 1998.
 
21) Yamamoto H, Kasai K, Hamada C, et al. : Differences in corrective mode for divalent ions and parathyroid hormone between standard-andlow-calcium dialysate in patients on continuous ambulatory peritoneal dialysis--result of a nationwide survey in Japan. : Perit Dial Int. Jun 28 (Suppl 3) : S128-30, 2008.
 
22) Duncan R, Cochrance T, Bhalla C, et al. : Low calcium dialysate and hyperthyroidism. Perit Dial Int 16 (Suppl 1) : S499-S502, 1996.
 
23) Johnson DW, Rigby RJ, Mclntyre HD, et al. : A Randomized trial comparing 1. 25mmol/l calcium dialysate in CAPD patients. Nephrol Dial Transplant 11 : 88-93, 1996.
 
24) Avram MM, Sreedhara R, Avram DK, et al. : Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. Am J Kidney Dis 28 : 924-930, 1996.
PubMed
25) Nada B Dimkovic, Joanne Bargman, Stephen Vas, et al. : Normal or low initial PTH levels are not a predictor of morbidity/mortality in patients undergoing chronic peritoneal dialysis : Perit Dial Int Mar ; 22 : 204-210, 2002.
 
P.130 掲載の参考文献
1) Lindberg JS, Culleton B, Wong G, et al. : Cinacalcet HCL, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis : A Randomized, Double-blind, Multicenter Study. Journal of the American society of Nephrology 16 : 800-807, 2005.
PubMed
2) Sterrett JR, Storm J, Stummvoll H-K, et al. : Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68 : 10-17, 2007.
 
3) 秋澤忠男, 内田英二, 越川昭三, 他 : 血液透析施行中の二次性副甲状腺機能亢進症患者に対するKRN1493 (シナカルセト塩酸塩) 長期投与の効果 -長期投与試験 (前期第II相) -. 腎と透析 63 : 119-131, 2007.
Medical*Online
4) 田原英樹, 秋澤忠男, 塚本雄介, 他 : 血液透析施行中の二次性副甲状腺機能亢進症患者に対するKRN1493 (シナカルセト塩酸塩) 長期投与の効果 (2) -長期投与試験 II (第II相) -. 腎と透析 63 : 275-288, 2007.
Medical*Online
5) Brown EM, MAcLEoD RJ : Extracellular calcium sensing and extracelular calcium signaling. Physiol Rev 81-1 : 239-297, 2001.
 
6) Quarles DL : Extracellular calcium-sensing receptors in the parathyroid gland, kidney and other tissues. Curr Opin Nephrol Hypertens 12 : 349-355, 2003.
 
7) Ohashi N, Uematsu T, Nagashima S, et al. : The calcimimetic agent KRN1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. British Journal of Clinical Pharmacology 57 ; 6 : 726-734, 2004.
 
8) Padhi D, Harris RZ, Salfi M, et al. : No Effect of Renal Function or Dialysis on Pharmacokinetics of Cinacalcet (Sensipar/Mimpara). Clinical Pharmacokinetics 44 : 509-516, 2005.
 
9) 伊達敏行, 重松隆 : 透析液の適正カルシウム濃度-各種薬剤との関連-. 臨床透析 19 : 325-329, 2003.
 
10) Date T, Kawashita Y, Matsuzaki M : The administration of cinacalcet hydrochloride just before a haemodialysis session suppresses the transient rise in intact parathyroid hormone induced by a low-calcium dialysate : when should cinacalcet hydrochloride be administered? NDT Plus 6 : 463-464, 2008.
PubMed
11) 永野伸郎 : Calcimimeticsの現況-新しい副甲状腺機能亢進症治療薬シナカルセト塩酸塩-. 日本透析医会雑誌 21 ; 2 : 300-309, 2006.
 
12) Ray JM, Squires PE, Curtis SB, et al. : Expression of the Calcium-sensing Receptor on Human Antral Gastrin Cells in Culture. J Clin Invest 99 ; 10 : 2328-2333, 1997.
PubMed
13) Ceglia L, Harris SS, Rasumussen HM, et al. : Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy patients. Osteoporosis Int 20 : 71-78, 2009.
 
14) Diez JJ, Miguel JL, Codoceo R, et al. : Effect of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis. N. D. T 23 : 1387-1395, 2008.
 
15) Watson JW, Gonsalves SF, Fossa AA, et al. : The anti-emetic effects of CP-99, 994 in the ferret and the dog : role of the NK1 receptor. Br J Pharmacol 115 : 84-94, 1995.
PubMed
16) Padhi D, Salfi M, Harris RZ, et al. : The Pharmacokinetics of Cinacalcet are Unaffected Following Consumpution of High-and Low-Fat Meals. Am J Ther 14 : 235-240, 2007.
 
17) Schaefer RM, Bover J, Dellanna F, et al. : Efficacy of cinacalcet administered with the first meal after dialysis : the SENSOR Study. Clin Nephrology 70-72 : 126-134, 2008.
 
18) Block GA, Martin MB, deFrancisco ALM, et al. : Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. The New England of Medicine 350 : 1516-1525, 2004.
 
19) Dong BJ : Cinacalcet : An Oral Oalcimimetic Agent for the Management of Hyperparathyroidism. Clin Ther 27 : 1725-1751, 2005.
PubMed
20) Rodriguez ME, Almaden Y, Canadillas S, et al. : The Calcimimetic R-568 increases vitamin D receptor exprssion in rat parathyroid glands. Am J physiol Renal Physiol 292 : F1390-F1395, 2007.
 
21) 永野伸郎 : Calcimimetic drug-新たなエビデンスと将来展望-. 腎と透析 60 : 770-776, 2006.
 
22) 濱野高行 : Calcimimeticsの医療経済. Clinical Calcium 18 : 74-80, 2008.
 
23) 伊達敏行 : 新しい副甲状腺インターベンションの治療戦略- PECIT (ペキット : エタノール+calcitriol注入療法) の有用性-. 日本透析医学会誌 37 : 50-52, 2004.
 
P.142 掲載の参考文献
1) Brown EM, Gamba G, Riccardi D, et al. : Cloning and characterization of an extracellular Ca2+ -sensing receptor from bovine parathyroid. Nature 366 : 575-580, 1993.
PubMed
2) Handlogten ME, Shiraishi N, Awata H, et al. : Extracellular Ca2+ -sensing receptor is a promiscuous divalent cation sensor that responds to lead. Am J Physiol Renal Physiol 279 : F1083-F1091, 2000.
PubMed
3) Smajilovic S, Tfelt-Hansen J : Calcium acts as afirst messenger through the calcium-sensing receptor in the cardiovascular system. Cardiovasc Res 75 : 457-467, 2007.
 
4) Nagano N : Pharmacological and clinical propertles of calcimimetics : calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 109 : 339-365. 2006.
PubMed
5) 永野伸郎 : Calcimimeticsの現況-新しい副甲状腺機能亢進症治療薬シナカルセト塩酸塩-. 日本透析医会雑誌 21 : 300-309, 2006.
 
6) Conigrave AD, Quinn SJ, Brown EM : Cooperative multi-modal sensing and therapeutic implications of the extracellular Ca2+ -sensing receptor. Trends Pharmacol Sci 21 : 401-407, 2000.
PubMed
7) 永野伸郎, 古田孝之 : カルシウム受容体作動薬の創薬と現状. 腎と骨代謝 21 : 113-121, 2008.
 
8) 永野伸郎 : カルシウム受容体に作用する新しい薬剤の開発-副甲状腺機能亢進症治療薬としての可能性-. 透析会誌 32 : 19-26, 1999.
 
9) Brown EM, MacLeod RJ : Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81 : 239-297, 2001.
PubMed
10) Quarles LD : Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens 12 : 349-355, 2003.
PubMed
11) Pearce SH, Thakker RV : The calcium-sensing receptor : insights into extracellular calcium homeostasis in health and disease. J Endocrinol 154 : 371-378, 1997.
PubMed
12) 永野伸郎 : 新しい二次性副甲状腺機能亢進症治療薬 : シナカルセト塩酸塩 (レグパラ(R)錠) の基礎と臨床. 愛媛県臨床工学技士会誌 19 : 36-49, 2008.
 
13) Nagano N, Furuya Y, Miyata S, et al. : Simultaneous activation of parathyroid and renal calcium receptor by a calcimimetic compound produces similar clinical observations to autosomal dominant hypocalcemia (ADH) : Experimental animal model of ADH. J Bone Miner Res 14 : S222, 1999.
 
14) de Francisco AL, Izquierdo M, Cunningham J, et al. : Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant 23 : 2895-2901, 2008.
PubMed
15) 永野伸郎, 川田剛央, 和田倫斉 : カルシウム受容体作動薬 (calcimimetics) の薬理・臨床試験成績 ; 維持透析下の二次性副甲状腺機能亢進症治療薬 (シナカルセト塩酸塩, レグパラ(R)錠). 日薬理誌 132 : 301-308, 2008.
 
16) 東純一, 古屋良宏, 内田英二 : KRN1493 (シナカルセト塩酸塩) の健康成人男子を対象とした第I相臨床試験-単回経口投与時の薬物動態, 薬力学および安全性の検討-, 薬理と治療 35 : 941-951, 2007.
Medical*Online
17) Malluche HH, Monier-Faugere MC, Wang G, et al. : An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69 : 269-278, 2008.
 
18) Hebert SC, Cheng S, Geibel J : Functions and roles of the extracellular Ca2+ -sensing receptor in the gastrointestinal tract. Cell Calcium 35 : 239-247, 2004.
PubMed
19) Conigrave AD, Brown EM : Taste receptors in the gastrointestinal tract. II. L-amino acid sensing by calcium-sensing receptors : implications for GI physiology. Am J physiol Gastrointest Liver Physiol 291 : G753-G761, 2006.
 
20) Conigrave AD, Franks AH, Brown EM, et al. : L-amino acid sensing by the calciumsensing receptor : a general mechanism for coupling protein and calcium metabolism? Eur J Clin Nutr 56 : 1072-1080, 2002.
PubMed
21) Ceglia L, Harris SS, Rasmussen HM, et al. : Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants. Osteoporos Int 20 : 71-78, 2009.
PubMed
22) 谷口正智 : Calcimimeticsの副作用とさまざまな臓器への効果. CLINICAL CALCIUM 18 : 45-50, 2008.
 
23) 永野伸郎 : 二次性副甲状腺機能亢進症治療薬-Calcimimetics-. 内分泌・糖尿病科 27 : 145-153, 2008.
 
24) Bro S, Olgaard K : Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 30 : 606-620, 1997.
PubMed
25) Ogata H, Ritz E, Odoni G, et al. : Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14 : 959-967, 2003.
PubMed
26) Piecha G, Kokeny G, Nakagawa K, et al. : Calcimimetic R-568 or calcitriol : equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J physiol Renal Physiol 294 : F748-F757, 2008.
PubMed
27) Smajilovic S, Tfelt-Hansen J : Novel role of the calcium-sensing receptor in blood pressure modulation. Hypertension 52 : 994-1000, 2008.
PubMed
28) Kawata T, Nagano N, Obi M, et al. : Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 74 : 1270-1277, 2008.
PubMed
29) Al-Aly Z : The new role of calcimimetics as vasculotropic agents. Kidney Int 75 : 9-12, 2009.
PubMed
30) Koleganova N, Piecha G, Ritz E, et al. : A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 75 : 60-71, 2009.
 
31) Smajilovic S, Sheykhzade M, Holmegard HN, et al. : Calcimimetic, AMG 073, induces relaxation on isolated rat aorta. Vascul Pharmacol 47 : 222-228, 2007.
PubMed
32) Alam MU, Kirton Jp, Wilkinson FL, et al. : Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 81 : 260-268, 2009.
PubMed
33) Wada M, Kobayashi N, Furuya Y, et al. : Expression of the calcium receptor in the primate endocrine pancreas. Diabetes 48 : A247, 1999.
 
34) Kwak JO, Kwak J, Kim HW, et al. : The extracellular calcium sensing receptor is expressed in mouse mesangial cells and modulates cell proliferation. Exp Mol Med 37 : 457-465, 2005.
PubMed
35) Riccardi D, Hall AE, Chattopadhyay N, et al, : Localization of the extracellular Ca2+/Polyvalent cation-sensing protein in rat kidney. Am J Physiol 274 : F611-F622, 1998.
PubMed
P.157 掲載の参考文献
1) Moe S, Drueke T, Cunningham J, et al. : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006.
PubMed
2) Coen G : Calcimimetics, parathyroid hor-mone, and vascular calcification in chronic kidney disease. Kidney Int 74 : 1229-1231, 2008.
 
3) Wetmore JB, Quarles LD : Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease : time for a paradigm shift? Nat Clin Pract Nephrol 5 : 24-33, 2009.
 
4) DrUeke TB, Ritz E : Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 4 : 234-241, 2009.
PubMed
5) Quarles LD, Sherrard DJ, Adler S, et al. : The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14 : 575-583, 2003.
PubMed
6) Block GA, Martin KJ, de Francisco AL, et al. : Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 : 1516-1525, 2004.
PubMed
7) Lindberg JS, Culleton B, Wong G, et al. : Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis : A randomized, double-blind, multicenter study. J Am Soc Nephrol 16 : 800-807, 2005.
PubMed
8) Fukagawa M, Yumita S, Akizawa T, et al. : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysls patients. Nephrol Dial Transplant 23 : 328-335, 2008.
PubMed
9) Strippoli GF, Palmer S, Tong A, et al. : Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47 : 715-726, 2006.
PubMed
10) National Kidney Foundation : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3) : S1-S201, 2003.
 
11) Guideline Working Group, Japanese Society for Dialysis Therapy : Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12 : 514-525, 2008.
 
12) Moe SM, Chertow GM, Coburn JW, et al. : A chieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 : 760-771, 2005.
 
13) Arenas M, Alvarez-Ude F, Gill M, et al. : Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 22 : 1639-1644, 2007.
 
14) Komaba H, Fukagawa M : lmpact of cinacalcet hydrochloride on the achievernent of the Japanese Society for Dialysis Therapy (JSDT) guideline targets : a post-hoc analysis of the KRN1493 study. Ther Apher Dial 12 (Suppl 1) : S44-S49, 2008.
 
15) Chertow GM, Blumenthal S, Turner S, et al. : Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calciurn x phosphate. Clin J Am Soc Nephrol 1 : 305-312, 2006.
PubMed
16) Messa P, Mac白rio F, Yaqoob M, et al. : The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 : 36-45, 2008.
 
17) Block GA, Zeig S, Sugihara J, et al. : Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 23 : 2311-2318, 2008.
PubMed
18) Fishbane S, Shapiro WB, Corry DB, et al. : Cinacalcet HCl and concurrent Iow-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone : the ACHIEVE study results. Clin J Am Soc Nephrol 3 : 1718-1725, 2008.
 
19) St Peter WL, Li Q, Liu J, et al. : Cinacalcet Use Patterns and Effect on Laboratory Values and Other Medications in a Large Dialysis Organization, 2004 through 2006. Clin J Am Soc Nephrol 4 : 354-360, 2009,
 
20) Cannata-Andia JB, Fernandez-Martin JL, Zoccali C, et al. : Current management of secondary hyperparathyroidism : a multicenter observational study (COSMOS). J Nephrol 21 : 290-298, 2008.
PubMed
21) Cunningham J, Danese M, Olson K, et al. : Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 : 1793-1800, 2005.
PubMed
22) Chertow GM, Pupim LB, Block GA, et al. : Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) : rationale and design overview. Clin J Am Soc Nephrol 2 : 898-905, 2007.
PubMed
23) Cheung AK, Levin NW, Greene T, et al. : Effects of high-flux hemodialysis on clinical outcomes : Results of the HEMO study. J Am Soc Nephrol 14 : 3251-3263, 2003.
PubMed
24) Wanner C, Krane V, Marz W, et al. : Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238-248, 2005.
PubMed
25) Narayan R, Perkins RM, Berbano EP, et al. : Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD : a cost utility analysis. Am J Kidney Dis 49 : 801-813, 2007.
PubMed
26) Garside R, Pitt M, Anderson R, et al. : The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in endstage renal disease : a UK perspective. Nephrol Dial Transplant 22 : 1428-1436, 2007.
PubMed
27) Ray JA, Borker R, Barber B, et al. : Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health 11 : 800-808, 2008.
PubMed

書評

最近チェックした商品履歴

Loading...